@article{8e860c933a3c4f45af83fe2b53421cb2,
title = "Percutaneous coronary intervention use in the United States: Defining measures of appropriateness",
abstract = "Appropriate utilization of percutaneous coronary intervention (PCI) and medical therapy is deservedly a national healthcare policy priority for the United States. Because PCI is both common and costly, appraisal of appropriateness is warranted. The initial appropriate use criteria (AUC) have been developed for coronary revascularization procedures and investigators recently reported the appropriateness for the approximately 500,000 PCI procedures performed at centers participating in the National Cardiovascular Data Registry. The AUC have broad implications for both healthcare providers and our patients and will be used as the basis for indications, referral patterns, treatment options, physician education, shared decision-making, and reimbursement for years to come. While we acknowledge the importance of thoughtfully assessing appropriateness for all medical procedures including PCI, there are a number of concerns with the current AUC and methods used to report appropriateness that warrant expanded commentary.",
keywords = "appropriateness, percutaneous coronary intervention, public reporting, quality",
author = "Marso, {Steven P.} and Teirstein, {Paul S.} and Kereiakes, {Dean J.} and Jeffrey Moses and John Lasala and Grantham, {J. Aaron}",
note = "Funding Information: Dr. Marso reports no personal conflicts of interest during the previous 24 months; all compensation for his research activities, including research grants and consulting fees from The Medicines Company , Novo Nordisk , Abbott Vascular , Amylin Pharmaceuticals , Boston Scientific , Volcano Corporation , and Terumo Medical , are paid directly to the Saint Luke's Hospital Foundation of Kansas City. Dr. Teirstein has received research grants, speakers fees, and consultant fees from Abbott , Boston Scientific , and Medtronic . Dr. Kereiakes has received grant and/or research support from Abbott Vascular , Cordis / Johnson & Johnson , Boston Scientific , Medtronic , and Edwards Lifesciences ; and consulting fees from REVA Medical Inc., Boston Scientific, and Abbott Vascular. Dr. Moses is a consultant for Abbott and Boston Scientific. Dr. Lasala is an advisory board member for Boston Scientific. Dr. Grantham has relationships with Abbott Vascular, Bridgepoint Medical, and CTOfundamentals.org (not-for-profit organization). ",
year = "2012",
month = feb,
doi = "10.1016/j.jcin.2011.12.004",
language = "English (US)",
volume = "5",
pages = "229--235",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "2",
}